US equities
|
MU
$1,065.30
▲+1.89%
SNDK
$1,713.07
▲+3.17%
NVDA
$237.81
▼-0.60%
AMD
$642.65
▼-1.04%
INTC
$113.97
▲+1.31%
SPCX
$168.07
▼-2.24%
TSLA
$375.63
▼-1.33%
MRVL
$281.74
▼-1.84%
MU
$1,065.30
▲+1.89%
SNDK
$1,713.07
▲+3.17%
NVDA
$237.81
▼-0.60%
AMD
$642.65
▼-1.04%
INTC
$113.97
▲+1.31%
SPCX
$168.07
▼-2.24%
TSLA
$375.63
▼-1.33%
MRVL
$281.74
▼-1.84%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
OS Therapies Incorporated Common Stock
(NY:
OSTX
)
1.525
+0.035 (+2.35%)
Delayed Quote
Updated: 10:48 AM EDT, Oct 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about OS Therapies Incorporated Common Stock
< Previous
1
2
3
4
5
Next >
OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial
October 06, 2026
72.7 percent three-year overall survival vs. 45.8 percent comparable combined historical control (p = 0.0006)Company preparing to complete submissions for...
Via
Newsfile
OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer
October 01, 2026
Experienced biotech leaders to focus on preparations for U.S., U.K., and European commercial launch of the Company's lead product candidate...
Via
Newsfile
OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)
September 24, 2026
New York, New York and Rockville, Maryland--(Newsfile Corp. - September 24, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS...
Via
Newsfile
OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis
September 21, 2026
Recent U.K. MHRA Scientific Advice Meeting (SAM) that resulted in full alignment to initiate confirmatory Phase 3 trial in U.K....
Via
Newsfile
OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program
September 17, 2026
FDA aligns with MHRA and EMA on adaptive design for Phase 3 trialAfter successful Scientific Advice Meeting, Company accepts MHRA...
Via
Newsfile
OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing
September 15, 2026
Overall Survival (OS) historical-control data gains HMRA and EMA support for pending CMAA submissionsFull alignment achieved on confirmatory Phase 3...
Via
Newsfile
OS Therapies Reports Strong Survival Data for Bone Cancer Treatment
↗
September 08, 2026
OS Therapies (NYSE: OSTX) interim Phase 2b trial data shows a 71.2% 3-year overall survival rate for OST-HER2 vs. 45.8% for controls.
Via
Benzinga
OS Animal Health Featured in Coverage of the Disruptive Growth & Life Sciences Conference
September 08, 2026
Via
Investor Brand Network
OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial
September 08, 2026
71.2% 3-year overall survival for OST-HER2-treated patients vs. 45.8% comparable combined historical control (p = 0.002)The two remaining patients who...
Via
Newsfile
InvestorNewsBreaks – OS Therapies Inc. (NYSE American: OSTX) Heads to Moody Capital Conference Amid Major OST-HER2 Regulatory Push
September 03, 2026
Via
Investor Brand Network
OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance
September 02, 2026
Management will participate at Jefferies Global Healthcare Conference, H.C. Wainwright Global Investment Conference, ROTH Healthcare Opportunities Conference Management and business...
Via
Newsfile
OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates
August 17, 2026
Up to $10 million debt financing supported by U.K. subsidiary VAT refunds and reimbursable R&D tax credits, including $5 million...
Via
Newsfile
OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma
August 13, 2026
Meeting to occur in mid-September 2026Interim 3-year Overall Survival data expected early September, 2026Decisions on appropriate comparator arm to interpret...
Via
Newsfile
OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program
July 08, 2026
New York, New York and Rockville, Maryland--(Newsfile Corp. - July 8, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS...
Via
Newsfile
Topics
Intellectual Property
OS Therapies Third Quarter 2026 Corporate Outlook
July 06, 2026
New York, New York and Rockville, Maryland--(Newsfile Corp. - July 6, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS...
Via
Newsfile
OS Therapies Appoints Dr. Craig Eagle to Board of Directors
July 02, 2026
Company secures $10 million line of credit supported by OS Therapies UK tax creditsNew York, New York and Rockville, Maryland--(Newsfile...
Via
Newsfile
OS Therapies Provides U.S. Regulatory Update
June 30, 2026
Type B Meeting requested to follow up on September 2025 End of Phase 2 FDA Meeting guidance on statistical methods...
Via
Newsfile
OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcoma
June 26, 2026
20% of OST-HER2 treated dogs survived 2-year vs. 1% in control group (p = 0.00995)Over 15,000 dogs per year diagnosed...
Via
Newsfile
OS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic Osteosarcoma
June 08, 2026
Confirmatory Phase 3 trial to commence prior to BLA grant under Accelerated Approval Program in the U.S. and Conditional MAA...
Via
Newsfile
Topics
Intellectual Property
OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma
June 02, 2026
75% 2.5-year overall survival for OST-HER2 vs. 47% pooled historical control ...
Via
Newsfile
Topics
Death
Intellectual Property
OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World
May 29, 2026
The Company confirms that it will release 2.5 year overall survival data from Phase 2b clinical trial OST-HER2 in the...
Via
Newsfile
OS Therapies to Attend Upcoming Medical, Financial and Industry Conferences
May 26, 2026
ASCO 2026: 2.5-Year Overall Survival DataJefferies Healthcare Conference: Partnering & Investor meetingsBIO International Convention: Panel ParticipationMIB Agents Factor Osteosarcoma Conference:...
Via
Newsfile
OS Therapies Reports First Quarter 2026 Financials and Provides Business Update
May 18, 2026
$5.5 million financing that closed on April 2, 2026 together with $5.7 million in capital raised in Q1-2026, expected to...
Via
Newsfile
Topics
Regulatory Compliance
OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026
May 15, 2026
New York, New York and Rockville, Maryland--(Newsfile Corp. - May 15, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS...
Via
Newsfile
OS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical Advisor
May 14, 2026
Appointment strengthens medical, regulatory, and commercial leadership as Company prepares to complete early market access regulatory filings in the U.S.,...
Via
Newsfile
Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX)
May 12, 2026
Dallas, Texas--(Newsfile Corp. - May 12, 2026) - OS Therapies Inc. (NYSE American: OSTX): Stonegate Capital Partners updates their coverage...
Via
Newsfile
OS Therapies Announces EMA Initiates Rolling Review of Conditional Marketing Authorization Application for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected Pulmonary Metastatic Osteosarcoma
April 30, 2026
Conference call scheduled for Thursday, April 30, 2026, at 8:30 am ET to review new OST-HER2 immune pharmacodynamic biomarker response...
Via
Newsfile
OS Therapies Schedules OST-HER2 Pharmacodynamic Response Biomarker Conference Call on April 30, 2026 at 8:30am ET
April 27, 2026
Regulatory feedback recent from April 2026 EU EMA and Australian TGA meetingsRemaining Q2-2026 regulatory meetings include two U.S. FDA meetings...
Via
Newsfile
Topics
Intellectual Property
OS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenes
April 16, 2026
New patent application covers treatment-emergent immune signature related to 'turning cold tumors hot' and the activation of targeted cytotoxic cellular...
Via
Newsfile
Topics
Intellectual Property
OS Therapies Appoints Biotech Industry Luminary Robert "Bob" S. Langer, PhD as Strategic Advisor
April 13, 2026
Co-founder of more than 40 biotechnology companies, including 16 IPOs and 19 successful acquisitions Scientific and medical titan focused on...
Via
Newsfile
< Previous
1
2
3
4
5
Next >
